A male patient underwent an aquablation procedure for symptomatic benign prostatic hyperplasia (bph).Procept biorobotics corporation (procept) became aware that while the patient was in the post anesthesia care unit, he began to experience pain and blood loss.Additionally, he experienced a vasovagal response which was stabilized.The patient was taken back into the operating room where clot evacuation was performed.Cautery was also performed to treat three sources of bleeding in the bladder.Two days post procedure, upon discharge, the patient's vitals were taken and it was noted that his o2 levels were at 88%.Testing for pulmonary embolism was performed which was inconclusive.The patient remained in the hospital and received a blood transfusion.The next day, the patient became hypoxic, and further testing performed confirmed pulmonary embolism.The patient was subsequently started on a 24 hour heparin drip.Two days later the patient was discharged.The patient was seen during a follow-up appointment on (b)(6) 2024 and was reported to be doing okay.It was reported that the patient remains on anticoagulant medication.No malfunction of the aquabeam robotic system was reported.
|
The aquabeam robotic system is a reusable device; therefore, it is still currently in possession of the user facility.The investigation of this event consisted of a review of the treatment log files, device history record (dhr), and labeling.The aquabeam robotic system's treatment logs file was reviewed, which confirmed no malfunctions during the aquablation procedure.The review of the treatment logs indicated that the system functioned as designed.A review of the device history record (dhr) for ab2000-b/serial number (b)(6) was performed, which confirmed that there were no non-conformances, failures, discrepancies, or missed steps during the manufacturing process that could be related to the reported event.The review indicated that the device met all design and manufacturing specifications when released for distribution.The aquabeam robotic system instructions for use ifu0101-00, rev.E, was reviewed and states the following: 4.3.Warnings: procedure.As with any surgical urologic procedure, potential perioperative risks of the aquablation procedure include: bleeding.The aquabeam robotic system's ifu lists bleeding and embolism as potential risks of the aquablation therapy and provides adequate instructions on how to achieve appropriate hemostasis.Based on the review of the treatment log files.Dhr, and ifu the event is considered not to be device-related.Submission of this report does not constitute an admission that the manufacturer's product caused or contributed to the event.
|